HEPHA-300

HEPHA-300 is a small molecule modulator of Toll-like receptor 4 (TLR4) currently under development by Hephaistos Pharma (also known as Hephai). The drug is specifically designed to target autoimmune diseases and auto-immune inflammation. While TLR4 is a well-known target in innate immunity, HEPHA-300 is positioned to address the aberrant inflammatory signaling associated with autoimmune conditions, likely through the inhibition or regulation of TLR4-mediated pathways. According to company pipeline documentation from late 2025, the program has advanced to Phase 2 clinical development, although earlier records from the same year listed it as being in the preclinical stage.